Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Login

    Gyre Therapeutics Inc.

    NASDAQ: GYRE · Real-Time Price · USD
    7.97
    -0.10 (-1.24%)
    At close: Jun 13, 2025, 3:59 PM
    7.89
    -1.00%
    After-hours: Jun 13, 2025, 04:20 PM EDT

    Gyre Therapeutics Statistics

    Share Statistics

    Gyre Therapeutics has 90.32M shares outstanding. The number of shares has increased by 0.96% in one year.

    Shares Outstanding

    n/a
    		 90.32M

    Shares Change (YoY)

    n/a
    		 0.96%

    Shares Change (QoQ)

    n/a
    		 0.59%

    Owned by Institutions (%)

    n/a
    		 1.94%

    Shares Floating

    n/a
    		 16.26M

    Failed to Deliver (FTD) Shares

    n/a
    		 2,454

    FTD / Avg. Volume

    n/a
    		 0.96%

    Short Selling Information

    The latest short interest is 1.42M, so 1.57% of the outstanding shares have been sold short.

    Short Interest

    n/a
    		 1.42M

    Short % of Shares Out

    n/a
    		 1.57%

    Short % of Float

    n/a
    		 9.66%

    Short Ratio (days to cover)

    n/a
    		 2.6

    Valuation Ratios

    The PE ratio is 85.2 and the forward PE ratio is 7.23. Gyre Therapeutics's PEG ratio is -0.78.

    PE Ratio

    n/a
    		 85.2

    Forward PE

    n/a
    		 7.23

    PS Ratio

    n/a
    		 9.74

    Forward PS

    n/a
    		 1.2

    PB Ratio

    n/a
    		 16.26

    P/FCF Ratio

    n/a
    		 -172.88

    PEG Ratio

    n/a
    		 -0.78
    Financial Ratio History

    Enterprise Valuation

    Gyre Therapeutics has an Enterprise Value (EV) of 1.02B.

    EV / Sales

    n/a
    		 9.64

    EV / EBITDA

    n/a
    		 57.22

    EV / EBIT

    n/a
    		 -279.99

    EV / FCF

    n/a
    		 -171.16

    Financial Position

    The company has a current ratio of 3.32, with a Debt / Equity ratio of 0.03.

    Current Ratio

    n/a
    		 3.32

    Quick Ratio

    n/a
    		 2.99

    Debt / Equity

    n/a
    		 0.03

    Debt / EBITDA

    n/a
    		 0.09

    Debt / FCF

    n/a
    		 -0.27

    Interest Coverage

    n/a
    		 0

    Financial Efficiency

    Return on Equity is 19.09% and Return on Invested Capital is 11.69%.

    Return on Equity

    n/a
    		 19.09%

    Return on Assets

    n/a
    		 9.64%

    Return on Invested Capital

    n/a
    		 11.69%

    Revenue Per Employee

    n/a
    		 $182,654.58

    Profits Per Employee

    n/a
    		 $20,872.19

    Employee Count

    n/a
    		 579

    Asset Turnover

    n/a
    		 0.84

    Inventory Turnover

    n/a
    		 0.61

    Taxes

    Income Tax

    n/a
    		 5.32M

    Effective Tax Rate

    n/a
    		 22.91%

    Stock Price Statistics

    The stock price has increased by -26.9% in the last 52 weeks. The beta is 2.19, so Gyre Therapeutics's price volatility has been higher than the market average.

    Beta

    n/a
    		 2.19

    52-Week Price Change

    n/a
    		 -26.9%

    50-Day Moving Average

    n/a
    		 8.98

    200-Day Moving Average

    n/a
    		 11.32

    Relative Strength Index (RSI)

    n/a
    		 43.3

    Average Volume (20 Days)

    n/a
    		 254,487

    Income Statement

    In the last 12 months, Gyre Therapeutics had revenue of 105.76M and earned 12.09M in profits. Earnings per share was 0.14.

    Revenue

    n/a
    		 105.76M

    Gross Profit

    n/a
    		 101.87M

    Operating Income

    n/a
    		 16.16M

    Net Income

    n/a
    		 12.09M

    EBITDA

    n/a
    		 17.82M

    EBIT

    n/a
    		 16.23M

    Earnings Per Share (EPS)

    n/a
    		 0.14
    Full Income Statement

    Balance Sheet

    The company has 11.81M in cash and 1.6M in debt, giving a net cash position of 10.21M.

    Cash & Cash Equivalents

    n/a
    		 11.81M

    Total Debt

    n/a
    		 1.6M

    Net Cash

    n/a
    		 10.21M

    Retained Earnings

    n/a
    		 -73.45M

    Total Assets

    n/a
    		 129.79M

    Working Capital

    n/a
    		 49.46M
    Full Balance Sheet

    Cash Flow

    In the last 12 months, operating cash flow was -3.64M and capital expenditures -2.31M, giving a free cash flow of -5.96M.

    Operating Cash Flow

    n/a
    		 -3.64M

    Capital Expenditures

    n/a
    		 -2.31M

    Free Cash Flow

    n/a
    		 -5.96M

    FCF Per Share

    n/a
    		 -0.07
    Full Cash Flow Statement

    Margins

    Gross margin is 96.33%, with operating and profit margins of 15.28% and 11.43%.

    Gross Margin

    n/a
    		 96.33%

    Operating Margin

    n/a
    		 15.28%

    Pretax Margin

    n/a
    		 21.95%

    Profit Margin

    n/a
    		 11.43%

    EBITDA Margin

    n/a
    		 16.85%

    EBIT Margin

    n/a
    		 15.28%

    FCF Margin

    n/a
    		 -5.63%

    Dividends & Yields

    GYRE does not appear to pay any dividends at this time.

    Dividend Per Share

    n/a
    		 n/a

    Dividend Yield

    n/a
    		 n/a

    Dividend Growth (YoY)

    n/a
    		 n/a

    Payout Ratio

    n/a
    		 n/a

    Earnings Yield

    n/a
    		 1.17%

    FCF Yield

    n/a
    		 -0.58%
    Dividend Details

    Analyst Forecast

    Currently there are no analyst rating for GYRE.

    Price Target

    n/a
    		 n/a

    Price Target Difference

    n/a
    		 n/a

    Analyst Consensus

    n/a
    		 n/a

    Analyst Count

    n/a
    		 n/a
    Stock Forecasts

    Fair Value

    There are several formulas that can be used to estimate the intrinsic value of a stock.

    Lynch Fair Value

    n/a
    		 n/a

    Lynch Upside

    n/a
    		 n/a

    Graham Number

    n/a
    		 1.54

    Graham Upside

    n/a
    		 -80.92%

    Stock Splits

    The last stock split was on Oct 31, 2023. It was a backward split with a ratio of 1:15.

    Last Split Date

    n/a
    		 Oct 31, 2023

    Split Type

    n/a
    		 backward

    Split Ratio

    n/a
    		 1:15

    Scores

    Altman Z-Score

    n/a
    		 20.81

    Piotroski F-Score

    n/a
    		 3

    Add to Watchlist